Related Experiment Video
Updated: Jan 13, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications
Yu Zhang1, Ningning Luo2, Minghui Ge2
1Pulmonary and Critical Care Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Objectives:
MET aberrations are capable of triggering oncogenesis through multiple clinical significance genomic alterations. In non-small cell lung cancer, MET exon 14 skipping and MET amplification confer sensitivity to MET tyrosine kinase inhibitors. The MET gene is also one of the druggable genes in high-grade gliomas. However, a systematic comparison of MET variations between lung cancer and brain tumors is lacking.
Methods:
We analyzed a large Chinese cohort of 30,355 lung cancer and 6004 brain tumor patients. Different MET mutation types were characterized, and somatic genomic mutational characteristics were examined across various MET mutation subgroups in both lung cancer and brain tumor cohorts. The impact of MET mutations on prognosis in these two cohorts was also assessed. The study cohort underwent comprehensive genomic profiling using targeted next-generation sequencing (NGS) panels.
Results:
We found that clinically significant MET mutations exist in both lung and brain tumor cohorts, with the lung cancer group having a higher overall frequency (p < 0.001), but the frequency of different MET mutation types, mutation characteristics, tumor mutation burden, and co-mutated genes with high frequency all differ. MET alterations were significantly enriched in post-treatment brain tumors (8.5% vs. 4.8% in treatment-naïve, p < 0.001). MET mutations also have different prognostic effects in the two cancer types. MET alterations were not prognostic in lung cancer but were associated with significantly poorer survival in brain tumors (median OS: 19.9 vs. 62.9 months, p < 0.001), a finding that held in multivariate analysis.
Conclusions:
Our study demonstrated that the biological and clinical significance of MET alterations is highly context dependent. In lung cancer, MET serves primarily as a predictive biomarker for targeted therapy, whereas in brain tumors, it functions as a prognostic marker of genomic instability and aggressive disease. These findings advocate for context-specific clinical management strategies.
Insights
MET alterations drive cancer, but their impact differs between lung and brain tumors. In lung cancer, MET mutations predict targeted therapy response. In brain tumors, MET alterations indicate aggressive disease and poorer survival.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- MET aberrations are key drivers in oncogenesis, with specific alterations like MET exon 14 skipping and amplification conferring sensitivity to targeted therapies in non-small cell lung cancer.
- The MET gene is also a target in high-grade gliomas, but a direct comparison of MET variations between lung cancer and brain tumors is lacking.
Purpose of the Study:
- To systematically compare MET gene alterations between lung cancer and brain tumor cohorts.
- To characterize the different types and frequencies of MET mutations in these two cancer types.
- To assess the prognostic impact of MET alterations in lung cancer and brain tumors.
Main Methods:
- Analysis of a large cohort of 30,355 lung cancer and 6004 brain tumor patients from China.
- Comprehensive genomic profiling using targeted next-generation sequencing (NGS) panels.
- Characterization of MET mutation types, somatic genomic mutational characteristics, and prognostic impact.
Main Results:
- Clinically significant MET mutations were found in both cohorts, with higher overall frequency in lung cancer (p < 0.001).
- MET alteration types, mutation characteristics, tumor mutation burden, and co-mutated genes differed significantly between the two groups.
- MET alterations were enriched in post-treatment brain tumors (8.5% vs. 4.8%, p < 0.001) and were associated with significantly poorer survival in brain tumors (median OS: 19.9 vs. 62.9 months, p < 0.001), but not in lung cancer.
Conclusions:
- The biological and clinical significance of MET alterations is context-dependent.
- In lung cancer, MET acts as a predictive biomarker for targeted therapy.
- In brain tumors, MET alterations serve as a prognostic marker for genomic instability and aggressive disease, necessitating context-specific management strategies.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
